Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GBT440 in Healthy Subjects and Sickle Cell Disease
NCT02285088Phase 1Completed
- Sponsor
- Global Blood Therapeutics
- Start
- Dec 2014
- Primary completion
- Mar 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in sickle cell disease (SCD) comparing GBT440 with Placebo (2 arms). Primary endpoint: Safety and Tolerability. Started Dec 2014; status: completed.
02
Drugs
voxelotor
03
Conditions
sickle cell disease (SCD)
Beyond the preview
Go deeper on NCT02285088.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02285088.